Sign in Sign up for free

Last updated: 1 July 2024 at 5:33pm EST

Michael Gilman Net Worth




The estimated Net Worth of Michael Gilman is at least $940 Thousand dollars as of 15 March 2021. Michael Gilman owns over 4,696 units of Scholar Rock Corp stock worth over $325,519 and over the last 20 years he sold SRRK stock worth over $425,379. In addition, he makes $188,661 as Independent Director at Scholar Rock Corp.

Michael Gilman SRRK stock SEC Form 4 insiders trading

Michael has made over 6 trades of the Scholar Rock Corp stock since 2004, according to the Form 4 filled with the SEC. Most recently he sold 4,696 units of SRRK stock worth $308,011 on 15 March 2021.

The largest trade he's ever made was exercising 30,000 units of Scholar Rock Corp stock on 13 September 2004 worth over $1,336,200. On average, Michael trades about 4,001 units every 355 days since 2004. As of 15 March 2021 he still owns at least 37,459 units of Scholar Rock Corp stock.

You can see the complete history of Michael Gilman stock trades at the bottom of the page.





Michael Gilman biography

Dr. Michael Gilman, Ph.D. is Independent Director of the company since November 2013. Dr. Gilman is currently Chief Executive Officer for Arrakis Therapeutics, Inc., a role he has served in since 2016. From October 2016 to April 2019, Dr. Gilman was Chief Executive Officer for Obsidian Therapeutics, Inc. Previously, from 2014 to 2016, Dr. Gilman was Founder and Chief Executive Officer of Padlock Therapeutics, Inc. Prior to Padlock, Dr. Gilman served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec Inc. from 2012 to 2013. He joined Biogen Idec Inc. in 2012 following its acquisition of Stromedix, Inc., where he was Founder and Chief Executive Officer. Prior to founding Stromedix in 2006, from 1999 to 2005, Dr. Gilman served in a variety of capacities, most recently as Executive Vice President, Research at Biogen Idec. From 1994 to 1999, Dr. Gilman was at ARIAD Pharmaceuticals, Inc., where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Dr. Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York. He also serves on the Board of Directors of Obsidian Therapeutics, Inc. and Novartis Venture Fund, and on the Scientific Advisory Board of FutuRx, an Israeli biotech accelerator. He previously served on the Board of Directors of X4 Pharmaceuticals, Inc. from September 2014 to March 2019. Dr. Gilman was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a Ph.D. in Biochemistry from University of California, Berkeley, and a S.B. in Life Sciences from Massachusetts Institute of Technology. Our Board of Directors believes that Dr. Gilman's extensive experience in the pharmaceuticals industry qualifies him to serve on our Board of Directors.

What is the salary of Michael Gilman?

As the Independent Director of Scholar Rock Corp, the total compensation of Michael Gilman at Scholar Rock Corp is $188,661. There are 6 executives at Scholar Rock Corp getting paid more, with Dr. Nagesh K. Mahanthappa MBA, Ph.D. having the highest compensation of $1,372,681.



How old is Michael Gilman?

Michael Gilman is 65, he's been the Independent Director of Scholar Rock Corp since 2013. There are no older and 13 younger executives at Scholar Rock Corp.

Insiders trading at Scholar Rock Corp

Over the last 6 years, insiders at Scholar Rock Corp have traded over $8,613,447 worth of Scholar Rock Corp stock and bought 8,895,194 units worth $64,726,758 . The most active insiders traders include Timothy A Springer, Srinivas Akkaraju, and Amir Nashat. On average, Scholar Rock Corp executives and independent directors trade stock every 55 days with the average trade being worth of $1,953,616. The most recent stock trade was executed by Caryn Parlavecchio on 16 August 2024, trading 1,451 units of SRRK stock currently worth $13,538.



What does Scholar Rock Corp do?

scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s



What does Scholar Rock Corp's logo look like?

Scholar Rock Holding Corp logo

Complete history of Michael Gilman stock trades at Biogen Inc and Scholar Rock Corp

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
15 Mar 2021 SRRK Scholar Rock Holding Corp Michael Gilman
Sale 4,696 $65.59 $308,011
15 Mar 2021
37,459 ↗
8 Feb 2021 SRRK Scholar Rock Holding Corp Michael Gilman
Sale 1,804 $65.06 $117,368
8 Feb 2021
42,155 ↗
26 Jan 2021 SRRK Scholar Rock Holding Corp Michael Gilman
Option 3,501 $5.77 $20,201
26 Jan 2021
47,460 ↗
28 Dec 2004 BIIB Biogen Inc Michael Gilman
EVP - Research
 Option 12,750 $44.95 $573,113
28 Dec 2004
28,750 ↗
9 Dec 2004 BIIB Biogen Inc Michael Gilman
EVP - Research
 Option 15,263 $40.93 $624,715
9 Dec 2004
23,287 ↗
13 Sep 2004 BIIB Biogen Inc Michael Gilman
EVP - Research
 Option 30,000 $44.54 $1,336,200
13 Sep 2004
44,500 ↗


Scholar Rock Corp executives and stock owners

Scholar Rock Corp executives and other stock owners filed with the SEC include: